glutamic acid and Ovarian Neoplasms

glutamic acid has been researched along with Ovarian Neoplasms in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (40.00)	29.6817
2010's	3 (60.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bronich, TK; Cohen, SM; Desale, SS; Kabanov, AV; Zhao, Y	1
Budczies, J	1
Andras, M; Dabby, R; Fishman, A; Gadoth, N; Karmon, Y; Levavi, H; Levi, T; Loven, D; Sabach, G; Zart, R	1
Aghajanian, C; Berger, MF; Dao, F; Delair, D; Garg, K; Grisham, RN; Hyman, DM; Iasonos, A; Iyer, G; Levine, DA; Solit, DB; Spriggs, DR; Zhou, Q	1
Buchmiller, LM; Charnsangavej, C; Hunter, N; Ke, S; Li, C; Milas, L; Tansey, W; Wallace, S; Wu, QP	1

Reviews

1 review(s) available for glutamic acid and Ovarian Neoplasms

Article	Year
[Metabolome analysis of solid tumors]. Der Pathologe, 2016, Volume: 37, Issue:Suppl 2 Topics: 4-Aminobutyrate Transaminase; beta-Alanine; Biomarkers, Tumor; Breast; Breast Neoplasms; Colonic Neoplasms; Female; Gas Chromatography-Mass Spectrometry; Glutamic Acid; Glutaminase; Glutamine; Humans; Metabolome; Neoplasms; Neoplasms, Hormone-Dependent; Ovarian Neoplasms; Ovary	2016

Trials

1 trial(s) available for glutamic acid and Ovarian Neoplasms

Article	Year
Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel. European journal of cancer care, 2009, Volume: 18, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Double-Blind Method; Female; Glutamic Acid; Humans; Middle Aged; Neurotoxicity Syndromes; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Treatment Outcome	2009

Article

Year

Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.

European journal of cancer care, 2009, Volume: 18, Issue:1

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Double-Blind Method; Female; Glutamic Acid; Humans; Middle Aged; Neurotoxicity Syndromes; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Treatment Outcome

2009

Other Studies

3 other study(ies) available for glutamic acid and Ovarian Neoplasms

Article	Year
Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer. Journal of controlled release : official journal of the Controlled Release Society, 2013, Nov-10, Volume: 171, Issue:3 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Delayed-Action Preparations; Female; Glutamic Acid; Humans; Mice; Mice, Nude; Micelles; Ovarian Neoplasms; Ovary; Paclitaxel; Phenylalanine; Polyethylene Glycols	2013
BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer, 2013, Feb-01, Volume: 119, Issue:3 Topics: Aged; Amino Acid Substitution; Biomarkers, Tumor; Cystadenoma, Serous; Early Detection of Cancer; Female; Gene Expression Regulation, Neoplastic; Glutamic Acid; Humans; Middle Aged; Mutation, Missense; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Proto-Oncogene Proteins B-raf; Survival Analysis; Valine	2013
Potentiation of ovarian OCa-1 tumor radioresponse by poly (L-glutamic acid)-paclitaxel conjugate. International journal of radiation oncology, biology, physics, 2000, Nov-01, Volume: 48, Issue:4 Topics: Animals; Dose-Response Relationship, Radiation; Drug Combinations; Female; Glutamic Acid; Mice; Ovarian Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radiobiology; Radiotherapy Dosage; Time Factors; Tumor Cells, Cultured	2000